Tasigna
Utilized to target specific protein kinases in chronic myeloid leukaemia and designed to alleviate disease progression in affected patients.
- Category
- Oncology Support
- Active ingredient
- Nilotinib
- Route
- Oral use
- Form
- Capsule, hard
- Strengths
- 150 · 200mg
You will receive a quality generic equivalent, depending on stock.
Prescription rules on Tasigna vary by country.
Tasigna details
- Condition
- Chronic Myeloid Leukaemia
- Therapeutic class
- Tyrosine Kinase Inhibitor
- Pharmacological class
- BCR-ABL Kinase Inhibitor
- Contraindications
- hypersensitivity to nilotinib; hypokalaemia; hypomagnesaemia; long QT syndrome
- Minor side effects
- nausea; rash; pruritus; headache
- Moderate side effects
- thrombocytopenia; neutropenia; hyperglycaemia
- Dosage forms
- Capsule, hard
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Originator
- Novartis
- Onset Time
- variable
- Duration
- continuous
- Storage instructions
- Store below 30°C.
- Drug interactions
- antacids; clarithromycin
- Age restrictions
- Not for children.
Precautions and warnings
monitor ECG for QT prolongation; avoid grapefruit juice; regular liver function monitoring
Serious side effects
qt prolongation, requires immediate medical attention; pancreatitis, requires immediate medical attention
Patient summary
utilized to target specific protein kinases in chronic myeloid leukaemia and designed to alleviate disease progression in affected patients.
Mechanism of action
Nilotinib is a highly selective inhibitor of the Bcr-Abl tyrosine kinase, which is the oncogenic driver of chronic myeloid leukaemia. It suppresses leukemic cell proliferation and induces apoptosis.
Pregnancy and breastfeeding
Pregnancy: Contraindicated as it may cause foetal harm. Breastfeeding: Not recommended.
What you will receive
Tasigna is the originator brand name, made by Novartis. We use it here to identify the medicine only; we are not affiliated with Novartis and do not ship the original Tasigna.
- You receive a generic equivalent: the same active ingredient (Nilotinib) at the same dose, mostly recognised Indian branded generics from vetted manufacturers.
- The exact brand supplied depends on what is in stock at the dispatching warehouse.
- A regulated generic matches the original ingredient for ingredient by legal standard.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Tasigna
Tasigna is a formulation of nilotinib, a medicine used for the management of Chronic Myeloid Leukaemia. The tablets are available in 150mg and 200mg strengths. Nilotinib acts as a targeted therapy to assist in managing the growth of abnormal white blood cells.
Tasigna availability in Asia
Tasigna is registered across 14 markets globally, including Malaysia, the Philippines and Indonesia, with availability also in Taiwan, South Korea and Japan. For patients residing across these regions, the medication provides a consistent option for disease management. It is best used under the ongoing care and supervision of a doctor.